
StudyFinder
RCT01437: Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with Crohn s disease: The OPTIMIZE Trial

Recruiting
The purpose of this study is to find out if using a computer program (called iDose) to guide infliximab dosing is more effective and safer than using standard infliximab dosing over 52 weeks. All patients in this study will be receiving infliximab as part of their medical care, this study is only looking at two different methods of determining the dose and timing of administration.
18 Years and over
Crohn Disease, Digestive & Liver Health
Clinics and Surgery Center (CSC)
Beiqing Wu - wu000948@umn.edu
Byron Vaughn
Phase IV
STUDY00013632
NCT04835506
See this study on ClinicalTrials.gov